| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/18/2009 | CN100462079C Externally applied sulfamylonum formulation and its preparation method |
| 02/18/2009 | CN100462078C Compound estradiol valerate tablet and its preparation process |
| 02/18/2009 | CN100462077C Perhexiline injection and its preparing method |
| 02/18/2009 | CN100462076C Stabilized oil-in-water emulsion of vinca alkaloids for vein and production thereof |
| 02/18/2009 | CN100462075C Nanometer miconazole nitrate emulsion medicine and its preparation process |
| 02/18/2009 | CN100462074C Chewing tablet with vision fatigue relieving function |
| 02/18/2009 | CN100462073C Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor |
| 02/18/2009 | CN100462072C Medicine composition used for injection and its preparing method |
| 02/18/2009 | CN100462071C Sustained release Brufen having magnetic super-molecular inserting layer structure and its preparation method |
| 02/18/2009 | CN100462070C Retinoic acid release control nanomicrosphere and its preparation method |
| 02/18/2009 | CN100462069C Valproic acid derivatives for the treatment of pain. |
| 02/18/2009 | CN100462068C Alphavbeta3 and alphavbeta6 integrin antagonists as antifibrotic agents |
| 02/18/2009 | CN100462067C Preparation method of sodium iron chlorophyllin-ethyl cellulose microcapsule |
| 02/18/2009 | CN100462066C Novel formulations of pharmacological agents, method for preparation thereof and method for use thereof |
| 02/18/2009 | CN100462019C Method of removing caffeine from caffeine-containing catechin compound composition |
| 02/17/2009 | US7492457 Methods and devices for testing germicide activity |
| 02/17/2009 | US7491849 Oligoamine compounds and derivatives thereof for cancer therapy |
| 02/17/2009 | US7491847 Methods for isolating propargylated aminoindans |
| 02/17/2009 | US7491844 Therapeutic cyclopentane derivatives |
| 02/17/2009 | US7491831 PPAR active compounds |
| 02/17/2009 | US7491829 e.g. 5-(1-(2-aminoethyl)-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydroinden-1-one oxime; serine/threonine (MAP) kinase inhibitor; antiiproliferative, aniinflammatory agent; neurodegenerative, cardiovascular diseases |
| 02/17/2009 | US7491827 Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
| 02/17/2009 | US7491826 Substituted urea derivatives activate the cardiac sarcomere by potentiating cardiac myosin; systolic heart failure including congestive heart failure; 1-[3-(1-Acetyl-piperidin-3-yloxy)-5-fluoro-phenyl]-3-(6-methoxy-pyridin-3-yl)-urea |
| 02/17/2009 | US7491825 e.g. N-[2-[4-(2-(S)-amino-6-dimethylamino-hexanoyl)-piperazin-1-yl]-1,1-dimethyl-2-oxo-ethyl]-2,4-dichloro-3-(2-methyl -quinolin-8-yloxy-methyl)-benzensulfonamide trifluoroacetate; antiinflammatory agent; asthma, chronic bronchitis, allergic rhinitis, obstructive pulmonary disease (COPD) |
| 02/17/2009 | US7491819 N-[4-Fluorophenyl)methyl]-4,6,7,9-tetrahydro-3-hydroxy-9,9-dimethyl-4-oxo-pyrimido[2,1-c][1,4]oxazine-2-carboxamide as an HIV integrase inhibitor |
| 02/17/2009 | US7491816 Antisense therapy for hormone-regulated tumors |
| 02/17/2009 | US7491815 Antisense modulation of C-reactive protein expression |
| 02/17/2009 | US7491805 Biological conjugates used for drug delivery; side effect reduction |
| 02/17/2009 | US7491794 Macrocyclic compounds as inhibitors of viral replication |
| 02/17/2009 | US7491748 e.g. (1) 3-(2-((naphthalen-1-ylmethyl)carbamoyl)-4-(2-methylphenoxymethyl)phenyl)propanoic acid; prostaglandin (PGE2) receptor ligand; analgesic, anticarcinogenic agent, antiallergen; neurodegenerative diseases |
| 02/17/2009 | US7491747 4-(Arylthio)- or (4-heteroarylthio)butyric acid derivatives that may be used in the treatment of dyslipidaemia, atherosclerosis and diabetes |
| 02/17/2009 | US7491746 Treating cell proliferation disorder, anticancer agents |
| 02/17/2009 | US7491745 e.g. 2-Ethyl-11-((3-methoxy-5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene)methyl)-10-azabicyclo[7.2.1]dodeca-9(12),11-diene; anticarcinogenic agent; antiproliferative agent, viricide; |
| 02/17/2009 | US7491744 Indoleacetic acid and indenacetic acid derivatives as therapeutic agents with reduced gastrointestinal toxicity |
| 02/17/2009 | US7491743 Inhibitors of cellular necrosis |
| 02/17/2009 | US7491742 Benzo(thio)pyrano[3,4-d]imidazol-4-(1H)-onederivatives; antiallergens, antiasthmatics, antitumor, antimetastasis, and antiinflammatory agents; bronchitis, dermatitis, psoriasis; autoimmune diseases; Crohn's disease, multiple sclerosis, AIDS |
| 02/17/2009 | US7491741 Diaminopropionic acid derivatives |
| 02/17/2009 | US7491740 Isoxazoline compounds having MIF antagonist activity |
| 02/17/2009 | US7491739 TNF-α production inhibitors |
| 02/17/2009 | US7491738 Pest control agents |
| 02/17/2009 | US7491737 Heterarylpiperidine modulators of chemokine receptor activity |
| 02/17/2009 | US7491736 Use as bronchodilators for treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-([4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino)ethyl)piperidin-4-yl ester |
| 02/17/2009 | US7491735 e.g. N-(3-{4-[(4-Bromo-phenyl)-(3-chloro-benzyl)-amino]-piperidin-1-yl}-butyl)-3,5-dichloro-isonicotinamide; viricide, antiinflammation agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV) |
| 02/17/2009 | US7491734 psychotic and intellectual impairment disorders; Alzheimer's disease, cognitive or attention disorders, antidepressant, anxiolytic agent; ,smoking cessation, neuroprotection, schizophrenia, analgesia, Tourette's syndrome, and Parkinson's disease |
| 02/17/2009 | US7491733 Bicyclic guanidine derivatives and therapeutic uses thereof |
| 02/17/2009 | US7491732 Compositions and methods for inhibition of the JAK pathway |
| 02/17/2009 | US7491731 Crystal structure of liganded cFMS kinase domain |
| 02/17/2009 | US7491730 Compositions useful as inhibitors of GSK-3 |
| 02/17/2009 | US7491729 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof |
| 02/17/2009 | US7491728 Pyrimidinone compounds as calcilytics |
| 02/17/2009 | US7491727 Arylpiperazinyl compounds |
| 02/17/2009 | US7491726 Characterized by x-ray powder diffraction pattern having peaks expressed as 2 theta at 8.7, 11.6, 16.3, 17.7, 18.6, 20.3, 23.4, 24.9 degrees; stable and reproducible; preparation via crystalline forms of aripiprazole hydrochloride serves as a means of producing pure aripiprazole |
| 02/17/2009 | US7491725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors |
| 02/17/2009 | US7491724 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases |
| 02/17/2009 | US7491723 Alkanol and cycloalkanol-amine derivatives and methods of their use |
| 02/17/2009 | US7491722 Pyridazin-3(2H)-one derivatives |
| 02/17/2009 | US7491721 N-(3-[[4-(3-trifluoromethylphenyl)piperazinyl]methyl]-2-methyl-5-phenyl-pyrrolyl)-4-pyridylcarboxamide; tuberculosis including multi-drug resistant and/or latent tuberculosis; antitubercular drugs |
| 02/17/2009 | US7491720 antitumor agent; 6-((4-(2-fluoro-3-(trifluoromethyl)benzoyl)piperazin-1-yl)methyl)-N-1H-pyrazol-3-ylpyrazin-2-amine; excellent potentiation; side effects reduction |
| 02/17/2009 | US7491719 adrenergic blocking agents such as R-6-Hydroxy-8-{1-hydroxy-2-[2-(4-methoxyphenyl)-1,1-dimethylethylamino]ethyl}-4H-benzo[1,4]oxazin-3-one hydrochloride, used for the treatment of repiratoty system disorders |
| 02/17/2009 | US7491718 Aminopeptidase inhibitor; vision defects; administering to eye |
| 02/17/2009 | US7491717 1-(3,4-dibromo-benzyl)-2-[4-(1-methyl-piperidin-4-yl)-piperazin-1-yl]-2-oxo-ethyl 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; analgesic, antidiabetic agent; migraine or cluster headaches, non-insulin-dependent diabetes |
| 02/17/2009 | US7491716 Glycogen synthase kinase-3 inhibitors such as [1-(4-Imidazo[1,2-a]pyridin-3-yl-2,5-dioxo-2,5-dihydro-1H-pyrrol-3-yl)-6,7-dihydro-6H-[1,4]diazepino[6,7,1-hi]indol-6-yl]-[morpholin-4-yl]methylenecyanamide, used for treating diabetes, Alzheimer's disease and for stimulating bone deposition in mammals |
| 02/17/2009 | US7491715 Analogs of clozapine; use with other neuropsychiatric agents; depression, anxiety, bipolar disorder, psychoses secondary to Alzheimer's or Huntington's disease |
| 02/17/2009 | US7491714 Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
| 02/17/2009 | US7491713 ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide |
| 02/17/2009 | US7491712 Process for preparation of paricalcitol and intermediates thereof |
| 02/17/2009 | US7491711 Methods of treatment using 3-desoxy vitamin D3 analogs |
| 02/17/2009 | US7491710 Organophosphorus derivatives of indazoles and use thereof as medicinal products |
| 02/17/2009 | US7491709 comprising injecting a bolus consisting of hyaluronic acid into the skin, to minimize wrinkles or folds in the skin |
| 02/17/2009 | US7491708 Modified pectin |
| 02/17/2009 | US7491707 Synthetic lipid-a-analogs and uses thereof |
| 02/17/2009 | US7491706 Containing a single-stranded oligonucleotide DNA molecule containing one or more CpG(s); SARS virus, hepatitis C virus, dengue virus and Japanese encephalitis, influenza virus |
| 02/17/2009 | US7491692 admixing a supplement selected from the therapeutically active agents for facilitating axon growth and a flowable carrier component capable of forming a matrix in vivo at a nerve lesion site and the active agent is releasable from the matrix |
| 02/17/2009 | US7491677 Composite sample on support; concentration gradients |
| 02/17/2009 | US7491550 Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2) |
| 02/17/2009 | US7491537 Nucleic acid formulations for gene delivery and methods of use |
| 02/17/2009 | US7491413 Compositions and methods for treating and preventing virus infections |
| 02/17/2009 | US7491411 dialysis or replacement fluid separated into two or more component solutions intended for admixture to use, provides the final dialysis or replacement fluid; aqueous NaHCO3 in one compartment, dissolved CO2 in separate compartment containing HCl or lactic or CH3COOH, NaCl, MgCl2, KCl, CaCl2, glucose |
| 02/17/2009 | US7491406 Fast dissolving orally consumable films |
| 02/17/2009 | US7491383 Solubilizer, and a anionic polymer or fatty acid in complex with a therapeutic |
| 02/17/2009 | US7491047 Delivery of antihistamines through an inhalation route |
| 02/17/2009 | CA2584845C Methods, assays and compositions for treating retinol-related diseases |
| 02/17/2009 | CA2535806C The use of hdac inhibitors for the treatment of cancer |
| 02/17/2009 | CA2518971C Composition for administration of iron for the treatment of restless legs syndrome |
| 02/17/2009 | CA2494825C Injectable pharmaceutical suspension in a two-chamber vial |
| 02/17/2009 | CA2445189C Carboline derivatives as pdev inhibitors |
| 02/17/2009 | CA2428315C Indole and dihydroindole derivatives |
| 02/17/2009 | CA2400217C Pteridine compounds for the treatment of psoriasis |
| 02/17/2009 | CA2383785C Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction |
| 02/17/2009 | CA2383555C 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| 02/17/2009 | CA2371925C Antibacterial compositions |
| 02/17/2009 | CA2356087C Methods and compositions for treatment of cell proliferative disorders |
| 02/17/2009 | CA2355283C Method for treatment of bacterial infections with once or twice-weekly administered rifalazil |
| 02/17/2009 | CA2348380C Aromatic derivatives and iron complexes thereof for the use as normalising agents of the iron level |
| 02/17/2009 | CA2347856C Dry powder for inhalation |
| 02/17/2009 | CA2334267C Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c |
| 02/17/2009 | CA2317691C Triazole derivatives having antifungal activity |
| 02/17/2009 | CA2301874C Suppression of malignancy utilizing ribonucleotide reductase r1 |
| 02/17/2009 | CA2299464C Controlled release pharmaceutical compositions containing tiagabine |
| 02/17/2009 | CA2257010C Methods and compositions for the treatment and prevention of tumors, tumor-related disorders and cachexia |